PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.06%
EBIT growth of 7.06% while Healthcare median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
7.06%
Operating income growth of 7.06% while Healthcare median is zero. Walter Schloss might see a modest advantage that can expand.
10.36%
Net income growth of 10.36% while Healthcare median is zero. Walter Schloss might see potential if moderate gains can keep rising.
28.30%
EPS growth exceeding 1.5x Healthcare median of 2.36%. Joel Greenblatt would confirm if consistent earnings expansion underpins these gains.
28.30%
Diluted EPS growth exceeding 1.5x Healthcare median of 2.22%. Joel Greenblatt would confirm if strong net income growth or buybacks drive outperformance.
24.68%
Share growth above Healthcare median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
24.68%
Diluted share growth above 2x Healthcare median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
17.79%
OCF growth of 17.79% while Healthcare is zero. Walter Schloss might see a modest positive difference, which can compound over time.
17.79%
FCF growth of 17.79% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19298.96%
Negative 10Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-3628.66%
Negative 5Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
45.61%
3Y OCF/share growth of 45.61% while Healthcare median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
-15204.15%
Negative 10Y net income/share CAGR vs. Healthcare median of 9.00%. Seth Klarman might see a fundamental problem if peers maintain growth.
97.68%
5Y net income/share CAGR > 1.5x Healthcare median of 5.10%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
59.13%
3Y net income/share CAGR > 1.5x Healthcare median of 5.49%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
9892.41%
Equity/share CAGR of 9892.41% while Healthcare median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
293.35%
5Y equity/share CAGR of 293.35% while Healthcare median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
201.29%
3Y equity/share CAGR of 201.29% while Healthcare median is zero. Walter Schloss sees a modest short-term advantage that could compound if momentum persists.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
67.39%
Asset growth of 67.39% while Healthcare median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
64.49%
BV/share growth of 64.49% while Healthcare is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
No Data
No Data available this quarter, please select a different quarter.
13.21%
R&D growth of 13.21% while Healthcare median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
-38.56%
SG&A decline while Healthcare grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.